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Cellular metabolism has been known for its role in bioenergetics. In recent years, much 
light has been shed on the reprogrammable cellular metabolism underlying many vital 
cellular processes, such as cell activation, proliferation, and differentiation. Metabolic 
reprogramming in immune and endothelial cells (ECs) is being studied extensively. 
These cell compartments are implicated in inflammation and pathogenesis of many 
diseases but their similarities in metabolic reprogramming have not been analyzed in 
detail. One of the most notable metabolic reprogramming is the Warburg-like effect, 
famously described as one of the hallmarks of cancer cells. Immune cells and ECs can 
display this phenotype that is characterized by a metabolic switch favoring glycolysis 
over oxidative phosphorylation (OXPHOS) in aerobic conditions. Though energy-ineffi-
cient, aerobic glycolysis confers many benefits to the respiring cells ranging from higher 
rate of adenosine triphosphate production to maintaining redox homeostasis. Chemical 
and biological regulators either promote or perturb this effect. In this review, nitric oxide, 
hypoxia-inducible factor, and adenosine monophosphate-activated protein kinase have 
been discussed for their common involvement in metabolic reprogramming of both sys-
tems. From in vitro and animal studies, various discrepancies exist regarding the effects 
of those regulators on metabolic switch. However, it is generally accepted that glycolysis 
favors inflammatory reactions while OXPHOS favors anti-inflammatory processes. The 
reasons for such observation are currently subject of intense studies and not completely 
understood. Finally, metabolic reprogramming in immune cells and ECs does not limit to 
the physiological state in health but can also be observed in pathological states, such as 
atherosclerosis and cancer. These new insights provide us with a better understanding 
of the similarities in metabolic reprogramming across a number of cell types, which 
could pave the way for future research and possible metabolic-based therapeutics.
Keywords: metabolism, metabolic reprogramming, glycolysis, oxidative phosphorylation, macrophage, 
T lymphocyte, endothelial cell
iNTRODUCTiON
Cellular metabolism has been sidelined for many years and it was only seen as the series of sequential 
pathways involved in converting fuel sources, such as glucose, fatty acids, ketones, and amino acids 
to generate packets of cellular energy in the form of adenosine triphosphate (ATP). At its infancy, 
scientists found it difficult to convince the scientific community that cellular metabolism and its 
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by-products might have wider implications on inflammation and 
disease pathogenesis (1). In 1997, Shim et al. conducted a study 
using representational difference analysis and found that lactate 
dehydrogenase (LDH)-A induction by the oncogene c-myc 
leads to overproduction of lactate (2). This finding provides a 
molecular explanation to the metabolism of tumor cells charac-
terized by glucose overutilization and lactate overproduction in 
normal oxygen conditions, also known as the Warburg effect. This 
reprogramming of cellular energetics in cancer cells is described 
as one of the ten hallmarks of cancer by Douglas Hanahan and 
Robert A. Weinberg in 2011 (3). With regard to lactate, it was 
recently found that the high levels of lactate present in the inflam-
matory microenvironment reduce the motility of T cells, hence 
serving an active retention mechanism and lead to the induction 
of T helper (TH)17 responses, which suggests that lactate is not 
merely a by-product of cellular metabolism, but it has a role 
in determining specific immune cell responses (4). There is an 
increasing awareness that many fundamental cellular processes, 
such as cell differentiation and proliferation have their distinct 
but reprogrammable metabolic requirements, which many 
experts would coin as the “renaissance of cellular metabolism.”
At the heart of these exciting findings, there is a growing 
interest in explaining well-established disease pathogenesis in 
the light of metabolic reprogramming. Inflammation is a tissue 
response to insult by host defense mechanisms. Although the 
inflammation is the bodily response to rid invading pathogens 
and promote healing of injured tissues, often unresolved chronic 
inflammation or dysregulated autoimmunity can be the core 
of many disease processes. In inflammation, endothelial cells 
(ECs) are responsible for controlling immune cell trafficking. 
Cells of the immune system are recruited to the site of injury via 
dilated tissue vasculature. With the lower shear stress in dilated 
vessels, immune cells accumulate at the margins of the lumen 
in proximity to the endothelium. The immune cells roll along 
and adhere firmly on the endothelium before migrating across 
the vessel in a process known as diapedesis. There is a major 
interplay between immune cells and ECs to orchestrate these 
complex series of events. Extensive studies on the metabolic 
reprogramming in both cells types are underway but little or no 
comparisons between these closely related systems exist in the 
current literature. Hence, this review will analyze and compare 
the similarities in metabolic reprogramming of endothelial and 
immune cells in both health and disease state and further discuss 
about possible therapeutic targets.
MeTABOLiC CHARACTeRiSTiCS OF 
MACROPHAGeS, T CeLLS, AND eCs
Macrophage Metabolism
Macrophages have been traditionally described by two 
differentiation pathways, which lead to the classical (M1) and 
the alternative (M2) phenotype (5). M1 and M2 phenotypes, 
however, are now known to belong to a spectrum of possible 
differentiation pathways alongside with numerous activation 
states with characteristic phenotypes. Recently, plaque-specific 
macrophages, such as M4, Mhem, and Mox, have been identified 
in atherosclerosis lesions (6–9). M2 macrophages can further be 
classified into M2a, M2b, M2c, and M2d subtypes (6, 10, 11). Xue 
et al. stimulated human macrophages with 28 different activation 
stimuli and analysis of the data has shown a spectrum of mac-
rophage activation states which does not conform to the classical 
bipolar M1/M2 axis (12). Despite the existence of a myriad of 
macrophage subsets, the M1/M2 paradigm is still extensively used 
in the literature and is a useful framework for the purpose of our 
discussion pertaining to macrophage metabolism and function.
In general, M1 macrophages are pro-inflammatory and 
they are functionally important for clearance of pathogens. 
M1 macrophage metabolism is characterized by high glycolysis 
and relatively low oxidative phosphorylation (OXPHOS), high 
inducible nitric oxide synthase (iNOS) activity, and nitric oxide 
(NO) production (13). The tricarboxylic acid (TCA) cycle of 
M1 macrophages is discontinuous and it has two break-points 
at isocitrate dehydrogenase and succinate dehydrogenase (SDH) 
(14). This observation provides explanation for the upstream 
accumulation of citrate and succinate, both of which influence the 
polarity of macrophages. Succinate acts as a pro-inflammatory 
signaling molecule by stabilizing hypoxia-inducible factor (HIF), 
a transcription factor which upregulates the biosynthetic capac-
ity of cells (15). Citrate is also a known pro-inflammatory signal. 
Citrate is involved in fatty acid and phospholipid biosynthesis 
that promotes the production of inflammatory prostaglandins 
(16). In the cytosol, the metabolism of citrate by ATP-citrate 
lyase generates nicotinamide adenine dinucleotide phosphate 
(NADPH) which is a required substrate for the synthesis of 
NO (17). Unlike naïve cell types, macrophages are terminally 
differentiated and they do not require energy for proliferation 
(18). Instead ATPs are used to sustain energy-demanding cellular 
activities, such as phagocytosis and secretory functions (18).
M2 macrophages, on the other hand, are involved in regen-
erative roles, such as tissue remodeling, repair, and healing. 
M2 macrophage metabolism is characterized by OXPHOS, 
fatty acid oxidation (FAO), and upregulated arginase 1 activity 
(13). Unlike M1 macrophages, the mitochondrial complexes in 
M2 macrophages are not occupied by NO and reactive oxygen 
species (ROS) and, hence, OXPHOS is sufficient to sustain the 
metabolic demand. M2 macrophages also express PFKFB1, an 
isoform of 6-phosphofructo-2-kinase capable of metaboliz-
ing the glycolytic activator fructose-2,6-bisphosphate (19). 
Abbreviations: ACC, acetyl-carboxylase A carboxylase; ADMA, asymmetric 
dimethylarginine; ADP, adenosine diphosphate; AMP, adenosine monophosphate; 
AMPK, AMP-activated protein kinase; ATP, adenosine triphosphate; CARKL, 
carbohydrate kinase-like protein; cGMP, cyclic guanosine monophosphate; ECs, 
endothelial cells; eNOS, endothelial nitric oxide synthase; ETC, electron transport 
chain; FAO, fatty acid oxidation; GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; GLUT, glucose transporter; HIF, hypoxia-inducible factor; HMGCR, 
3-hydroxy-3-methylglutaryl-CoA reductase; IDH, isocitrate dehydrogenase; IFN, 
interferon; iNOS, inducible nitric oxide synthase; LDH, lactate dehydrogenase; 
LPS, lipopolysaccharide; MHC, major histocompatibility complex; NADPH, nico-
tinamide adenine dinucleotide phosphate; NO, nitric oxide; OXPHOS, oxidative 
phosphorylation; PFK, phosphofructokinase-1; PPP, pentose phosphate pathway; 
ROS, reactive oxygen species; SDH, succinate dehydrogenase; SDMA, symmetrical 
dimethylarginine; TAMs, tumor-associated macrophages; TCA, tricarboxylic acid; 
TH, T helper; Treg, regulatory T; VEGF, vascular endothelial growth factor.
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As opposed to the upregulated pentose phosphate pathway (PPP) 
in M1 macrophage, PPP is suppressed in M2 macrophage by the 
expression of carbohydrate kinase-like protein (20). l-arginine 
metabolism via arginase produces ornithine, which is important 
for the synthesis of proline, a component of tissue collagen (21). 
Consequently, arginase activity might be driving the reparative 
function of M2 macrophages in tissue remodeling. Lastly, the 
predilection for OXPHOS and FAO in M2 macrophage is also 
driven by high adenosine monophosphate-activated protein 
kinase (AMPK) activity (22).
T Cell Metabolism
The role of T cells in the adaptive immune system is vast and they 
function by secreting lymphokines to induce immunomodula-
tory actions (CD4+) or by promoting cytotoxicity (CD8+). CD4+ 
T cells bind to major histocompatibility complex (MHC) class II 
ligands on antigen-presenting cells, while the counterpart, CD8+ 
T cells, bind to MHC class I ligands. There are several subtypes 
of CD4+ T  cell differentiation, including TH1, TH2, TH17, TH9, 
regulatory T (Treg) cell, follicular helper T cell, type 1 T regulatory 
cell, and memory T cells (23–25).
Naïve T  cells rely on FAO and OXPHOS for their energy 
production (26, 27). Upon encountering antigen-presenting cells, 
naïve T cells undergo activation and subsequently clonal expan-
sion and differentiation. During this period, profound metabolic 
changes occur. Activated T cells upregulate aerobic glycolysis and 
the glycolytic branch reaction, PPP (28, 29). This is attained via 
glucose transporter (GLUT) 1 translocation to cell periphery and 
upregulation of glycolytic enzymes (28, 30). Glutamine metabo-
lism is also enhanced which supplies products for the TCA cycle 
as well as promoting polyamine synthesis (29, 31).
Distinct metabolic pathways are required for differentiation of 
activated T cells. The T effector subsets, TH1, TH2, and TH17, are 
known to prefer glycolysis even in aerobic conditions (32, 33). 
Treg cells, on the other hand, mainly prefer FAO for energy 
generation and replicate at moderate levels as opposed to the 
profound amplification in cell proliferation seen in T effector cells 
(18, 33, 34). Metabolism of memory T cells is largely similar to 
that in naïve T cells, aside from the increased mitochondrial mass 
that is a preemptive measure to prepare for mitochondrial energy 
generation upon secondary antigen exposure (35).
eC Metabolism
Endothelial cells can be classified into three different subtypes 
based on their morphology and role in angiogenesis: the highly 
branched tip cells are primarily migratory and navigate the 
direction of the vessel sprout; the stalk cells have less branches 
but are highly proliferative and elongate the sprout during 
extension; and lastly, phalanx cells, commonly recognized by 
their cobblestone appearance, are quiescent and line the mature 
blood vessels (36). In maturity, majority of the blood vessels are 
relatively quiescent but they retain the capacity to respond to 
angiopoietin in physiological and pathological states to generate 
new blood vessels from existing vasculature, in a process known 
as angiogenesis (37). This sequential and highly coordinated pro-
cess can be accomplished by either sprouting or non-sprouting 
angiogenesis (37, 38).
Owing to the low mitochondrial content, ECs rely almost 
exclusively on glycolysis for energy generation (39). On vascular 
endothelial growth factor (VEGF) stimulation, the rate of glyco-
lysis is doubled and GLUT 1 expression is upregulated to meet 
the metabolic demand of cell migration during angiogenesis 
(40, 41). PFKFB3, a different isoform to PFKFB1 expressed in 
M2 macrophages, is also involved in the metabolic regulation of 
ECs. PFKFB3 stimulates glycolysis by synthesizing large quan-
tity of fructose-2,6-bisphosphate, which is a potent glycolytic 
stimulator (39). Glycolysis is shown to modulate the phenotypic 
expression of ECs. Increased activity of PFKFB3 could override 
genetically predestined stalk cells into metabolically active 
tip cells to further enhance ECs sprouting (39). Conversely, 
extracellular environment such as laminar shear stress exerted 
by blood flow lowers PFKFB3 activities and the associated 
metabolic changes that resultantly sustain cellular quiescence 
(42). Apart from angiogenesis, ECs are involved in a wide range 
of vascular homeostatic functions such as vasodilation and the 
anti-proliferating effect on vascular smooth muscle cells through 
the action of NO generated by endothelial nitric oxide synthase 
(eNOS) (43). As in the case with M2 macrophages, AMPK in ECs 
senses glucose deprivation and promotes the inhibition of acetyl-
coenzyme A carboxylase (ACC), resulting in increased FAO 
(44). Schoors et al. investigated FAO in ECs and found it essential 
for ECs proliferation during vessel sprouting, unlike glycolysis 
that regulates both proliferation and migration (45). The targeted 
control of FAO on ECs proliferation could potentially be a thera-
peutic option for pathological angiogenesis (Figure 1).
MeTABOLiC RePROGRAMMiNG  
iN THe iMMUNe CeLLS AND eCs
Cells derive energy from catabolism of the three major biomass 
sources: glucose, fatty acids, and amino acids mainly through 
glycolysis and OXPHOS. In theory, a molecule of glucose can 
yield up to approximately 38 molecules of ATP of which, 2 from 
glycolysis, 2 from the TCA cycle, and 34 from OXPHOS. Based 
on the number of moles of ATP produced per mole of glucose, 
OXPHOS would be the ideal and most efficient bioenergetic 
pathway. However, glycolysis is the preferred one in cells 
with high metabolic demands as it confers many benefits. The 
demand for an expensive amount of energy from metabolically 
active processes can be met by aerobic glycolysis, which is a 
faster bioenergetic pathway as compared to OXPHOS, granted 
that there is a steady stream of glucose supply (46). The meta-
bolic intermediates of glycolysis can also be shunted to branch 
reactions and synthetic pathways to generate macromolecules 
and maintain redox homeostasis needed for cell proliferation, 
migration, and maintaining physiological functions (17, 41, 47). 
M1-activated macrophages rely on glycolysis for ATP produc-
tion, while the mitochondrial machinery has been shunted 
to ROS production necessary for bactericidal activity (48). 
The enhanced glycolytic branch reaction PPP also augments the 
production of NADPH required for the production of ROS (49). 
In CD4+ T cells, it was shown that OXPHOS and aerobic gly-
colysis can interchangeably be used to sustain cell proliferation 
FiGURe 1 | A summary of the main bioenergetic pathways in each of the cell types discussed. It should be noted that glycolysis is the preferred bioenergetic 
pathway in classical pro-inflammatory cells and endothelial cells.
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cellular metabolism. Recent studies have shown that low plasma 
membrane cholesterol and functional connexin-based channels 
facilitate the transport of NO across cellular membranes (77, 78). 
These observations suggest that NO generated by ECs could exert 
its effect on immune cells in a paracrine fashion. In terms of cel-
lular production of NO, the substrate l-arginine can be shunted 
into two metabolic processes, either the iNOS or the arginase 
pathway. iNOS metabolizes l-arginine to produce NO and citrul-
line while arginase, on the other hand, controls the ornithine cycle 
by catalyzing the formation of ornithine and urea. Both enzymes 
compete for the same common substrate and, hence, NO produc-
tion and its effect on metabolism are controlled by the expression 
of these enzymes. Colegio et al. found that lactate generated from 
aerobic glycolysis could induce the expression of arginase 1 and 
M2-like phenotype in tumor-associated macrophages (TAMs) 
via the HIF pathway (79). This finding has implications for cancer 
cell survival and is further discussed in a later section.
A study on murine thymus shows that the nitrosylating effect 
of NO is also seen in other enzymes regulating the activity of 
glycolysis, the TCA cycle, and fatty acid metabolism (80). NO 
has a toxic effect on T cells, consistent with a role as self-limiting 
pathway in TH1 cell-mediated responses in  vivo via IFN-γ  
(56, 81). In an experimental study on autoimmune disorder, 
IFN-γ exerted a protective effect via activation of iNOS and 
production of NO (82). NO in turn triggered T cell apoptosis, 
thus providing some degree of explanation to the self-limiting 
effector response of TH1 cells (55). Addition of l-arginine to 
CD4+ T cells was shown to induce several metabolic changes, 
including increased gluconeogenesis, decreased GLUTs and 
glycolytic enzymes, and a metabolic switch to OXPHOS (53). 
A possible explanation is the upregulation of the serine bio-
synthetic pathway which fuels the TCA cycle and subsequently 
OXPHOS and results in a “reverse” Warburg-like effect (53, 54). 
T cells have also been shown to display a twofold decrease in 
glycolytic rate when iNOS is knocked-out (83). Alongside the 
apparent anti-inflammatory effect of NO on T cells, it was shown 
and survival, but only aerobic glycolysis can adequately lead to 
the attainment of full effector function (26, 31). ECs invariably 
utilize glycolysis as the main bioenergetic process and several 
advantages of aerobic glycolysis have been suggested. Despite 
the proximity to readily available oxygen sources, glycolysis 
reduces the need for oxygen and this allows maximum oxygen 
concentration carried in the blood to tissues perfused by the 
blood vessels (18). In neovascularization, ECs proliferate in 
order to perfuse hypoxic tissues. Low oxygen level in hypoxic 
environment limits the effectiveness of OXPHOS in generating 
ATP and, hence, glycolysis is preferred (18). Reaction–diffusion 
models show that the decrease in partial pressure of oxygen is 
less than the decrease in glucose concentration over distance 
(18, 50). This suggests that ECs can still undergo anaerobic 
glycolysis as tip cells get further away from blood vessels. 
In this review, NO, HIF, and AMPK will be discussed in more 
detail owing to their common involvement in the regulation of 
the Warburg-like effect and other forms of bioenergetics seen in 
all three cell types. Other potent metabolic regulators, such as 
mTOR, are not within the scope of this review as there is limited 
literature of its effect on ECs (18, 41). The main similarities and 
differences in the metabolic pathways of macrophages, T cells, 
and ECs are summarized in Table 1.
Nitric Oxide
Synergistic stimulation of macrophages by lipopolysaccharide 
(LPS) and interferon (IFN) has been shown to increase the 
expression of iNOS and NO production and resulting in a 
preferential switch to glycolysis (17, 51, 52). One of the pos-
sible mechanisms is via the nitrosylating effect of NO on iron-
sulfur proteins of the electron transport chain complex leading 
to inhibition of cell respiration (75, 76). iNOS-deficient dendritic 
cells are unresponsive to LPS stimulation but pharmacological 
reintroduction of exogenous NO results in a metabolic switch 
from OXPHOS to aerobic glycolysis (75). Several studies have 
shown that NO can permeate cell membranes to exert its effect on 
TABLe 1 | The similarities and differences in metabolic reprogramming mediated by nitric oxide (NO), hypoxia-inducible factor (HIF), and adenosine monophosphate-
activated protein kinase (AMPK) in macrophages, T lymphocytes and endothelial cells (ECs).
Macrophages T lymphocytes eCs
NO ↑ Glycolysis, ↓ oxidative phosphorylation (OXPHOS) (17, 51, 52) ↓ Glycolysis (53)
↑ OXPHOS (53, 54)
↑ Effector T cell apoptosis (55)
↑ Regulatory T (Treg) population (56)
↑ Glycolysis, ↓ OXPHOS (57, 58)
↓ Glyceraldehyde-3-phosphate 
dehydrogenase activity (59)
HIF ↑ Glycolysis (60–63) ↑ Glycolysis (29, 64)
↑ Th17 differentiation, ↓ Treg population (65)
↑ Glycolysis (66, 67)
AMPK ↑ Fatty acid oxidation (FAO), ↓ inflammatory response (68, 69)
↓ M1 macrophage polarization (70)
↑ Glycolysis in monocytes (71)
↓ Glycolysis (72)
↑ OXPHOS (73)
↓ Glycolysis (74)
↑ FAO (74)
On a whole, the metabolic changes induced by these metabolic signals are similar between the immune and endothelial systems. However, NO suppresses glycolysis in T cells, 
while AMPK upregulates glycolysis in monocytes, both of which do not conform to the general framework.
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that NO induces proliferation of functional Treg cell population 
(56). The metabolic mechanism behind the increased prolif-
eration of Treg cells by NO is not well understood but it may 
represent a key regulation point of host immune function.
Nitric oxide is arguably the most important synthetic product 
of ECs as it has a role in modulating vasodilation and inflam-
mation. eNOS is functionally similar to iNOS and it metabolizes 
l-arginine to citrulline and NO. Aside from its local effect on 
vascular smooth muscle cells, NO is also an autocrine signaling 
molecule and exhibits effects on ECs metabolism. In the angio-
genic state, the metabolic demand of ECs is greatly increased 
and this is met by increasing the rate of glycolysis (39–41). Using 
an NO-donor, it was shown that glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), a glycolytic enzyme in bovine aortic 
ECs is inhibited in a dose-dependent manner but the effect is 
reversed to near base-line upon removal of the NO-donor, which 
implies that GAPDH is a target for NO-mediated oxidative stress 
(59). The same group of researchers conducted another study 
and found that NO stimulates glycolysis and reversibly impairs 
mitochondrial reserve capacity (57). This set of data opposes the 
earlier finding on NO-mediated inhibition of GAPDH, leading 
to the conclusion that inhibition of this enzyme is not a sensi-
tive biological effect of NO (57). Other studies have also been in 
support of the action of NO in promoting glycolysis in ECs. Paik 
et al. treated human umbilical vein ECs with sodium nitroprus-
side and diethylenetriamine, both of which are NO donors and 
found that 18F-fluorodeoxyglucose uptake was increased along-
side with GLUT 1 expression and hexokinase activity (58). These 
changes are surrogate markers of increased glycolytic flux in ECs. 
Despite not many studies support a role for NO-mediated effects 
via rewiring of EC metabolism, NO produced from eNOS is 
theoretically capable of interacting with the immune system and, 
hence, it represents a topic of interest for further investigation.
Hypoxia-inducible Factor
In vitro and in vivo studies show that glycolytic flux is upregu-
lated by both M1 activation and hypoxic condition (60). Cellular 
adaptation to hypoxia is mediated by the transcription factor HIF 
(84). It is made of two subunits, HIF-1β and HIF-1α of which 
the latter is degraded by oxygen-dependent mechanisms (84). 
HIF-1α expression is induced by TH1 cytokine stimulation and 
is known to promote the metabolic switch from OXPHOS to gly-
colysis by regulating the activity of GLUT 1 and several enzymes 
in the glycolytic pathway (61). HIF-1α also increases LDH and 
reduces pyruvate dehydrogenase activity, collectively shunting 
the production of acetyl-CoA for the TCA cycle to the produc-
tion of lactate inducing the Warburg-like effect in macrophages 
(62, 63). Interestingly, Takeda et al. found that in TH1 cytokine-
induced M1 macrophages, HIF-1α induces the expression of 
iNOS but not arginase, while the converse is true for HIF-2α in 
M2 macrophages (85).
Wang et al. found that glycolysis, glutamine metabolism, and 
FAO were not affected by short-term (24  h) deletion of HIF-
1α but mild glycolysis impairment was shown after 72  h with 
moderate downregulation of LDH-A and hexokinase-2 gene 
expression (29). Despite the data suggesting a limited role of 
HIF-1α in promoting the reprogramming of T cell metabolism, 
HIF-1α-deficient CD4+ T  cells cultured in TH17-stimulating 
conditions show lower expression of genes encoding for GLUTs, 
LDH-A, and other glycolytic enzymes (64). Interestingly, HIF 
has also been shown to regulate the TH17/Treg balance by favor-
ing TH17 differentiation and suppressing Treg population (65). 
This is also apparent in TH17-mediated autoimmune disease as 
in vivo studies showed that mice with HIF-1α-knock out T cells 
were resistant to experimental autoimmune encephalitis (65). 
It is known that TH17 cells favor glycolysis, while Treg cells rely 
on OXPHOS and FAO for energy generation. This experiment 
provides indirect evidence for a possible link between HIF and 
the Warburg-like effect seen in T cells.
Similar metabolic adaptation to hypoxia is also seen in ECs. 
An experiment on bovine aorta and human umbilical ECs shows 
that, in hypoxic conditions, ECs increase glucose uptake and 
lactate generation, both of which are surrogates for glycolysis 
activity (66). The team then inhibited OXPHOS under aerobic 
conditions and an upregulation of GLUTs in ECs was observed 
over several hours. The authors suggest that the lag period 
is observed as a result of a series of events involving mRNA 
transcription and protein translation of the GLUTs (66). Oswald 
et al. studied the effect of hypoxia on the metabolism of ECs from 
three different sources, namely umbilical, dermal, and aortic. 
The expression of HIF and VEGF mRNA as markers of experi-
mental hypoxia was measured and they found that hypoxia is 
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associated with increased uptake of 18F-fluorodeoxyglucose by 
ECs from all tissue sources (67). The authors concluded that 
the low oxygen tension stabilizes HIF-1α that is involved in the 
upregulation of GLUT-1 expression (67).
Adenosine Monophosphate-Activated 
Protein Kinase
Adenosine monophosphate-activated protein kinase is 
known as the metabolite-sensing kinase and is activated in 
conditions of low energy and oxygen reserve (17, 86). The 
breakdown product of ATP, adenosine monophosphate 
(AMP), and adenosine diphosphate (ADP) bind to AMPK 
making it more susceptible to activation by upstream 
kinases (17, 87). AMPK has been shown to play a role in 
regulating mitochondrial bioenergetic reactions. One pro-
posed pathway is by directly upregulating mitochondrial 
biogenesis through the induction of its transcriptional coac-
tivator, proliferator-activated receptor-γ-coactivator-1 that 
induces mitochondrial biogenesis and respiration (88, 89). 
AMPK also induces the activity of SDH in the TCA cycle that 
fuels OXPHOS (90). Another notable function of AMPK is the 
modulation of mTOR as one of its downstream targets. mTOR 
acts as an intracellular sensor to metabolic cues and directs the 
rate of cell growth and proliferation (91). Depletion of ATP 
activates AMPK that in turns inhibits mTOR and subsequent 
protein synthesis in order to conserve energy (92). Aside from 
that, AMPK also has a role in upregulating FAO by inhibiting 
ACC, a rate-limiting enzyme for the carboxylation reaction 
of acetyl-CoA to malonyl-CoA (93). However, the study 
outcomes on the importance of AMPK in FAO have not been 
always congruent. Recent evidence shows that skeletal muscles 
with AMPK kinase-dead mutant display ACC phosphoryla-
tion, reduction in malonyl-CoA, and FAO rate similar to those 
in controls (94). Nonetheless, these data are not retrieved 
from studies on immune cells or ECs but rather conducted in 
skeletal muscles for their abundance in mitochondria content.
Stimulation by M2 stimuli, such as IL-10 and TGF-β rapidly 
activates AMPK (70). Inhibition of AMPK by genetic deletion 
of its subunits leads to a heightened inflammatory response 
and reduction in FAO, a key bioenergetic pathway in M2 mac-
rophages (68, 69). These observations are in concordance with 
the role of AMPK in opposing the polarization of M1-activated 
macrophages (70). In one occasion, AMPK has been shown to 
increase glycolysis in monocytes during hypoxia by activating the 
glycolytic stimulator, PFKFB3 (71). O’Neill and Hardie proposed 
that this observation could be explained as an ATP-generating 
function of AMPK by activated macrophages during hypoxia 
(22). Another interesting theory from Luo et al. based on their 
work on tumor cells describes that AMPK induces glycolysis 
and FAO in acute stress, whereas chronic AMPK stimulation 
dampens glycolysis via inhibition of mTOR and its action on 
p53 tumor suppressor protein, albeit the evidence for the latter 
is limited (95). The relevance of this dual effect of AMPK on the 
metabolism of macrophages requires further investigation.
Although TH1, TH2, and TH17 subtypes of activated CD4+ 
T cells adopt glycolysis as their main form of energy generation, 
Treg cells, on the other hand, rely mainly on fatty acid metabo-
lism (18, 33, 34). Metformin, a known inducer of AMPK, was 
shown to increase the number of Treg cells in murine studies (33). 
To find out the direct role of AMPK on Treg cells metabolism, 
genetic methods were employed and it was shown that knock out 
of the AMPKα1 subunit increases GLUT-1 expression and hexoki-
nase activity (72). This resulted is a threefold increase in basal 
glycolytic rate observed in T-cells supporting the role of AMPK 
in hindering the switch to aerobic glycolysis (72). However, the 
cells did not display any polarization toward pro-inflammatory 
subtypes despite an increase in glycolysis (72). Mayer et al. found 
that T cells in AMPK-deficient mice displayed increased rate of 
cell death and reduced aerobic glycolysis as compared to wild-type 
T  cells when mitochondrial respiration is artificially inhibited, 
which suggests the role of AMPK as a response mechanism to 
metabolic stress (96). T cell activation and cytokine production, 
on the other hand, remain intact in AMPK-deficient mice (96). 
Blagih et  al. conducted another study by subjecting T  cells to 
glucose-scarce environment, which inhibited glycolysis. They 
found that AMPK is essential for glutamine-dependent OXPHOS 
when glucose supply is limited, providing further evidence for 
the role of AMPK in T cell response during metabolic stress (73). 
Functionally, although AMPK-deficient T cells display full prolif-
erative capacity when glucose supply is not a limiting factor, the 
same scenario is not true when glucose supply is low (73). In vivo 
experiments show that the T cell population was relatively smaller 
in AMPK-deficient mice as compared to wild-type controls (73). 
There was no difference observed in viral load but there was a 
reduction in bacterial clearance in the AMPK-deficient group 
(73). Taken together, these observations show that despite the 
AMPK-induced metabolic reprogramming seen in T cells, AMPK 
might not display an overt in vitro effect on T cell function, such as 
activation and differentiation. However, AMPK could be essential 
for T cell function in metabolic stress and in vivo environment 
where the cellular micromilieu is more variable.
Although the name suggests otherwise, AMP has not been 
shown to be responsible for the activation of AMPK in ECs. 
Alternative stimuli, such as the increase in ADP/ATP ratio, 
tumor suppressor gene product LKB1, shear stress exposure, 
and Ca2+-elevating agonists, such as bradykinin and thrombin, 
have been proposed (87, 97–99). Similar to the observations 
seen in M1 macrophages and Treg cells, AMPK activation was 
shown to reduce glucose uptake and glycolysis in ECs (74). ECs 
are known to generate up to 85% of their total ATP through 
glycolysis (39). Therefore, endothelial mitochondria have been 
proposed to serve other functions other than solely being the 
energy powerhouse of the ECs. The expression of mitochon-
drial antioxidant enzymes induced by AMPK has shown to 
confer protective benefit to ECs against oxidative stress (100). 
Apart from its effect on glucose metabolism, AMPK activa-
tion has been shown to increase FAO in human umbilical 
vein ECs (74). Specifically, palmitate oxidation is heightened 
from the activation of AMPK by bradykinin, suggesting that 
AMPK activation may mitigate lipotoxicity secondary to fatty 
acid accumulation in the initial stages of atherosclerosis (98) 
(Figure 2).
FiGURe 2 | [1] Glycolysis, [2] tricarboxylic acid (TCA) cycle and oxidative phosphorylation, [3] fatty acid oxidation, [4] pentose phosphate pathway, [5] ornithine 
cycle, and [6] glutamine metabolism. This figure shows the main metabolic pathways in relation with nitric oxide (NO), hypoxia-inducible factor (HIF), and adenosine 
monophosphate-activated protein kinase (AMPK). NO is produced by NOS with l-arginine as the substrate while succinate, the intermediate of the TCA cycle 
stabilizes and activates HIF. Adenosine triphosphates (ATPs) are hydrolyzed to adenosine diphosphate (ADP), while some are converted to adenosine 
monophosphate (AMP) via adenylyl cyclase. The increase in AMP/ADP:ATP ratio as well as other extracellular metabolic stressors activate AMPK. The effect of 
these mediators on metabolic reprogramming is listed in Table 1. PFKFB3 converts fructose-6-phosphate to fructose-2,6-bisphosphate, which in turn activates 
phosphofructokinase-1 and promotes the rate of glycolysis. Citrate metabolism produces acetyl-CoA, which is converted to malonyl-CoAs for fatty acid synthesis. 
Arachidonic acid and its derived inflammatory prostaglandins are produced from the same pathway. Arginase regulates the ornithine cycle, which is involved in the 
production of polyamines, a prominent feature of metabolism in M2 macrophages.
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CeLLULAR MeTABOLiSM  
iN iNFLAMMATiON
Atherosclerosis from a Perspective  
of Cellular Metabolism
Despite being largely seen as a lifestyle disease, a large part of 
atherosclerosis stems from inflammation. The earliest evidence 
of atherosclerosis in a human’s lifetime is fatty streaks, which 
are inflammatory lesions found in blood vessels, even in those 
of infants and young children. As described earlier, NO has 
several homeostatic functions in the circulatory system, includ-
ing modulating vasodilation, inhibiting platelet aggregation, 
and smooth muscle proliferation, all of which if dysfunctional 
will result in atherosclerosis. In ECs, an imbalance of antia-
therogenic NO versus its counterpart, the proatherogenic ROS 
such as superoxides, is often described in early atherosclerosis 
(101–103). eNOS uncoupling also occurs when l-arginine 
supply is limited, generating ROS instead of NO (104). On the 
other hand, administration of l-arginine over 13 weeks has also 
been shown to regress atherosclerotic lesions in rabbits with 
hypercholesterolemia, suggesting reversibility in atherosclerosis 
progression through the restoration of NO action (105). In a 
study, plasma level of l-arginine, asymmetric dimethylarginine 
(ADMA), and symmetrical dimethylarginine in 49 patients with 
hypercholesterolemia were compared with the controls and 
it was found that increased ADMA associates with impaired 
vasodilation and reduction in urinary nitrate (106). These effects 
were shown to be reversible upon l-arginine administration in a 
double-blinded, randomized, placebo-controlled cross over study 
and the researchers concluded that ADMA can serve as a novel 
risk factor for cardiovascular disease (106). It is postulated that 
ADMA is a competitive inhibitor of NOS, which at high levels 
results in reduction of NO synthesis (107). This competitive inhi-
bition could then be overcome by increasing the plasma level of 
l-arginine.
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The inflammatory process of atherosclerosis is dependent 
on the balance of pro-inflammatory and anti-inflammatory 
cells (108, 109). In early atherogenesis, TH1 cytokines, such as 
IFN-γ, and lipoprotein, activate M1 macrophages that liberate 
more pro-inflammatory cytokines (110). M2 macrophages, on 
the other hand, were shown to counteract inflammation and pro-
mote healing (21). Regulation of this balance could be a potential 
therapeutic option for atherosclerosis. Some regulators such as 
peroxisome proliferator-activated receptor gamma coactivators 
1β were shown to induce OXPHOS and FAO in macrophage 
population and to enhance the maturation of anti-inflammatory 
M2 macrophages (110). Induction of M2 macrophages can also 
be achieved via AMPK activation (111). Accumulation of M2 
macrophages in vivo was found to decreases the size of athero-
sclerotic plaques in mice with hypercholesterolemia (111).
Although most T effector responses aggravate atherosclerosis, 
Treg cells activity was shown to reduce the size of lesions and 
extent of inflammation (112, 113). In a murine study, injection of 
anti-CD3 antibody was shown to induce the Treg cell population 
and promote regression of atherosclerotic lesions. This beneficial 
effect was abolished soon after injection of anti-CD25 antibody 
that depleted Treg cells (114). Macrophages with increased expres-
sion of enzymes involved in the synthesis of retinoic acid, such 
as aldehyde dehydrogenase 1A2 and retinal dehydrogenase were 
shown to increase Treg cell population (111). This is in tandem 
with the role of retinoic acid in supporting differentiation of Treg 
cells from naïve T cells (115).
Patients with cardiovascular risks are classically treated 
with statins, a drug that inhibits HMG-CoA reductase, a rate-
controlling enzyme of the mevalonate pathway that leads to 
the production of cholesterol. HMG-CoA reductase inhibition 
via statins, however, causes reduced immunosuppressive activ-
ity by Treg cells, an effect that could limit the therapeutic effect 
of statins (116, 117). Restoration of Treg cell function can be 
achieved through administration of mevalonate, the product of 
3-hydroxy-3-methylglutaryl-CoA reductase enzymatic reaction 
(116, 117). The role of mevalonate as an adjunctive treatment 
for lipid-lowering statin regimen is also an interesting topic for 
clinical research. These discoveries are exciting as they open new 
ways of treating this extensively studied condition, which has 
plagued the humanity since the beginning of modernization.
The Survival Mechanisms of Cancer Cells
In neoplasm, growing tumors proliferate at an exceedingly fast 
rate, rendering the micromilieu deprived of glucose and amino 
acids essential for T cell function (118–120). This is in concord-
ance with the importance of metabolic pathways in controlling 
cellular functions. T cells assume an effector status by upregulat-
ing glycolytic and anabolic activities through increased glucose 
uptake, glutamine oxidation, and oxygen consumption (27). 
The glucose-scarce micromilieu perturbs these energy-expensive 
processes and sends CD4+ T cells into dormancy known as the 
anergy state and, subsequently, T  cell dysfunction (119–121). 
CD4+ T cells that have undergone metabolic inhibition and anergy 
fail to proliferate even upon re-challenging with costimulation, 
which is the signal required for T  cells to achieve full effector 
status and maximal expression of cytokines (121). Furthermore, 
lactate accumulation secondary to tumor glycolysis from the 
Warburg effect leads to acidosis in the microenvironment (122). 
High levels of lactate have been shown to inhibit T cell motility 
and glycolysis via distinct transporters exhibited by CD4+ and 
CD8+ T  cells (4). This inhibition coupled with HIF-induced 
upregulation of programmed cell death-ligand 1 grants tumor 
cells immunity against cytotoxic effect of T cells (119, 120, 123). 
In terms of NO, T cell cytotoxicity can be hindered as a result of 
peroxynitrite formation from the rapid interaction of ROS and 
NO generated by tumor iNOS from l-arginine metabolism (118).
To contribute to the existing complexity, M2 TAMs are also 
implicated in tumor cell survival. As mentioned before, M2 
TAMs have heightened arginase activity that converts l-arginine 
to ornithine and urea, further depleting the limited local source of 
l-arginine. Ornithine induces the polarization of more M2 TAMs 
and, hence, this leads to the development of a vicious circle (124). 
The competition for l-arginine hampers the ability of M1 TAMs 
to generate NO that has antitumor properties (124). The scarcity 
of l-arginine also has a knock-on effect on T cell function as they 
also depend on l-arginine for NO and protein synthesis, both 
of which are required for T cell activation. In short, tumor cells 
have developed a distinctive reprogrammed metabolism that 
provides survival advantage by fast-tracking energy production 
and anabolic processes while in the process also creates the per-
fect microenvironment to hinder the metabolism and antitumor 
function of immune cells.
Tumor ECs, on the other hand, have overexpression of GLUTs, 
which is indicative of rapid glucose uptake and glycolytic activ-
ity (40, 41). Perivascular NO gradient has been shown in vitro 
to facilitate blood vessel normalization and maturation (125). 
As seen in the competition with immune cells for metabolic sub-
strate, increased uptake of l-arginine by cancer cells reduces NO 
generated by eNOS. This results in the formation of abnormal 
vessels in terms of organization, structure, and function, prov-
ing a challenge for delivering antitumor drugs to the perfused 
cancer cells (125). Recently, upregulation of PFKFB3, a key 
regulator of ECs glycolysis, was shown to lead to the develop-
ment of immature and dysfunctional vasculature in tumor 
angiogenesis (39, 41, 126). Further to that, inhibition of the 
enzyme results in normalization of blood vessels and, hence, it 
could be a potential therapeutic target as an adjunctive treatment 
for effective delivery of modern cytotoxic agents to tumor cells 
(39, 41, 126). At the same time, heightened glycolysis in tumor 
cells is PFKFB3-dependent and inhibition of the same enzymes 
was shown to reduce glucose uptake and proliferation of human 
hematopoietic and adenomatous cancer cell lines (127).
The clinical implication of cell metabolism in oncology is vast. 
Since the year 2000, lactate accumulations have been reported by 
several teams as prognostic predictors of poor outcome in patients 
with solid malignant tumors (128). Several glycolytic inhibitors 
have also been shown to be effective therapeutic adjuncts against 
cancers in hypoxic environment and those with mitochondrial 
defects that are resistant to conventional chemoradiotherapies 
(129). Although the theoretical advantage of glycolysis inhibitors 
is to devoid tumor cells of ATP by inhibiting their main mode 
of bioenergetics, it is postulated that cancer cells with intact 
mitochondria could still generate ATP through OXPHOS. The 
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other advantage of inhibiting glycolysis is to normalize the 
acidic tumor micromilieu and the subsequent reestablishment of 
tumor-suppressing immune function. Arginine metabolism has 
also attained great interest in cancer therapeutics and, interest-
ingly, both upregulation and inhibition of arginase action can 
lead to tumor-suppressing activities. Tumor growth displayed 
dose-dependent suppression on administration of arginase 
inhibitor and the effect is not seen in mice with dysfunctional 
adaptive immune system, suggesting that the antitumor activity 
of arginase inhibitor is immune mediated (130). On the other 
hand, supplementation of recombinant human arginase was 
shown to induce cell apoptosis in non-small cell lung cancers 
through mitochondrial-derived ROS production (131). However, 
arginase supplementation reduces l-arginine required for the 
T-cell proliferation and cell–cycle progression from the accumu-
lation of myeloid-derived suppressor cells (MDSC), suggesting a 
need for co-targeting MDSC accumulation in arginase inhibitor 
cancer treatments (132). At the moment, the knowledge of cel-
lular metabolism is pushing the boundaries of modern oncology 
but the in  vivo effect of metabolic reprogramming remains 
ambiguous in certain conditions.
PeRSPeCTive AND CONCLUSiON
The impact of metabolism on cell function is an area with great 
future prospect for research. For example, NO has been shown to 
selectively induce differentiation of naïve CD+ 4 T cells into TH1 
phenotype (56). Although both TH1 and TH2 cells utilize aerobic 
glycolysis as their main source of bioenergetics, the reasons for 
NO to selectively induce TH1 differentiation are not completely 
understood (33). It is exciting and equally challenging to find out 
methods to translate our knowledge on metabolic reprogram-
ming into therapeutics of human diseases. Seeing the fact that 
bioenergetic mechanisms are ubiquitous in all cell lines, often the 
big question in therapeutics may be the systemic side effects of 
metabolic-based treatments as a result of unintended involve-
ment of bystander cells. To illustrate, a partial and reversible 
reduction of glycolysis can be achieved through PFKFB3 block-
ade with an intention to reduce proliferation, migration, and 
sprouting of ECs (133). Potentially, the enzyme blockade could 
sufficiently reduce pathological progression of atherosclerosis 
while sparing healthy vasculature from permanent glycolytic 
dysfunction. Furthermore, pathogenesis of some well-described 
diseases could be seen from a different light with new under-
standing in metabolic reprogramming. Recently, novel research 
on endothelial dysfunction in rheumatoid arthritis is underway 
(134). ROS is found to be directly implicated in synovitis associ-
ated with rheumatoid arthritis (135). Patients with rheumatoid 
arthritis also have raised plasma ADMA, a known cause of 
NO-mediated endothelial dysfunction (136). These new findings 
could lead to the development of treatment adjuncts to couple 
with the current regimen largely based on immunosuppressants 
such as methotrexate. These examples are milestones we have 
achieved in a relatively short span of time, a testimony of the 
tremendous potential in the field of cellular metabolism. Cellular 
functions are highly dependent on the metabolic requirement; 
understanding the metabolic pathways will inform us with novel 
approaches to exploit these functions in the light of therapeutic 
and translational opportunities.
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